Subsequently, TNT003, a mouse monoclonal anti-C1s antibody that targets C1s serine protease activity, has been shown to block classical complement pathway activation and prevent C3d deposition and phagocytosis of red blood cells exposed to CAD patient plasma; it also completely inhibited hemolysis in vitro [16]. The gene discussed is C1S; the disease is cold agglutinin disease.